1.

List of soldiers and diary of Fr. Francis A. Gleeson 10 - 11 November 1917 ; Fr. Francis A. Gleeson Papers

2.

List of soldiers and diary of Fr. Francis A. Gleeson 10 - 11 November 1917 ; Fr. Francis A. Gleeson Papers

3.

List of soldiers and diary of Fr. Francis A. Gleeson 10 - 11 November 1917 ; Fr. Francis A. Gleeson Papers

4.

List of soldiers and diary of Fr. Francis A. Gleeson 10 - 11 November 1917 ; Fr. Francis A. Gleeson Papers

1.

Transcript of List of soldiers and diary of Fr. Francis A. Gleeson 10 - 11 November 1917 ; Fr. Francis A. Gleeson Papers

2.

Transcript of List of soldiers and diary of Fr. Francis A. Gleeson 10 - 11 November 1917 ; Fr. Francis A. Gleeson Papers

3.

Transcript of List of soldiers and diary of Fr. Francis A. Gleeson 10 - 11 November 1917 ; Fr. Francis A. Gleeson Papers

4.

Transcript of List of soldiers and diary of Fr. Francis A. Gleeson 10 - 11 November 1917 ; Fr. Francis A. Gleeson Papers

1.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

2.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

3.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

4.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

5.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

6.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

7.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

8.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

9.

Development of species-specific enzyme-linked immunosorbent assay for diagnosis of Johne's disease in cattle

1.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

2.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

3.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

4.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

5.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

6.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

7.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

8.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

9.

How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

1.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

2.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

3.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

4.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

5.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

6.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

7.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

8.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

9.

Substantial use of primary health care by prisoners: epidemiological description and possible explanations.

1.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

2.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

3.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

4.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

5.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

6.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

7.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

8.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

9.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

1.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

2.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

3.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

4.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

5.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

6.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

7.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

8.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

9.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

1.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?

2.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?

3.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?

4.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?

5.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?

6.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?

7.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?

8.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?

9.

Chilblains and COVID-19: can recent epidemiological data shed light on the aetiological debate?